Arbutus Biopharma Corporation (NASDAQ:ABUS) has scheduled a conference call for 7th August 2020 at 8:45 AM Eastern Time to announce its 2Q20 financial results.
The conference call will also be webcast live under the investor relations section of the website www.arbutusbio.com
Earnings Expectation
Arbutus Biopharma Corporation is expected to report second quarter earnings results, before market open, on Friday 7th August 2020. Analysts polled by Thomson Reuters anticipate second quarter loss of $ 0.24 per share from revenue of $ 1.74 million. Looking ahead, the full year loss are expected at $ 0.91 per share on the revenues of $ 7.09 million.
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. Its HBV product pipeline consists of AB-506, a capsid inhibitor that has shown improved potency and pharmacokinetics over its first generation capsid inhibitor; and AB-423, which is in pre-clinical studies. The company also develops RNAi drugs, which utilize the RNA interference pathway, allows for a novel approach to treating disease.
